Polycythemia Vera Gets a First-in-Class Option. Patients Need More Than Blood Draws.
FDA has approved rusfertide for erythrocytosis in adults with polycythemia vera. The approval targets the biology behind red-blood-cell overproduction and may reduce phlebotomy burden. That…
Polycythemia Vera Gets a First-in-Class Option. Patients Need More Than Blood Draws.
Parkinson’s Risk Is Not One Thing
MRSA May Have A New Weakness
Cardiovascular AI is getting better. That does not mean it is getting fairer
Cardiometabolic risk leaves a protein signature in childhood. Could it guide prevention decades earlier?
IPM Brief – Issue 28 | The Currency of Time
HER2 Testing Just Became the Gatekeeper in Gastroesophageal Cancer
Explore by disease area
Cardiology
Mapping prevention, diagnostics and access pathways for cardiovascular care.
Cardiometabolic
Tracking risk, prevention and access in metabolic and vascular health.
Eye Disease
Following diagnostics, treatment access and equity in vision care.
Infectious disease
Tracking diagnostics, resistance, prevention and access across infection pathways.
Neurology
Mapping early diagnosis, biomarkers and access in brain health.
Oncology
Following testing, treatment access and equity across cancer pathways.
Alerts
See all →Polycythemia Vera Gets a First-in-Class Option. Patients Need More Than Blood Draws.
HER2 Testing Just Became the Gatekeeper in Gastroesophageal Cancer
MS Gets a Cleaner BTK Signal
Mpox Finally Gets A Stockpile
Brain Tumour Surgery Is Getting Smaller. Access Cannot Stay Elite.
AMR Has An Equity Problem
Brain Tumour Surgery Is Getting Smaller. Access Cannot Stay Elite.
Canada Moves. Alzheimer’s Patients Still Wait.
Prostate Cancer Treatment Is Creating a Metabolic Bill
Hodgkin Lymphoma Survivors Are Still Paying for Cure
Signals
See all →
Cardiovascular AI is getting better. That does not mean it is getting fairer
Cardiometabolic risk leaves a protein signature in childhood. Could it guide prevention decades earlier?
MRSA May Have A New Weakness
Researchers in Ireland have found that several drugs used in cancer treatment can make MRSA more vulnerable to penicillin-type antibiotics in laboratory experiments. One compound…
Playbook
See all →
IPM Brief – Issue 28 | The Currency of Time
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 27 | The Fine Print Is Practising Medicine
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 26 | Science Has Left Home. Policy Hasn’t
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 25 | August ignored your out-of-office
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 24 | Medicine refused to stay in its lane
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
By subscribing, you agree to receive updates from IPM Alliance. You can unsubscribe at any time. For more information, please see our Privacy Policy.
